A quadrivalent vaccine against serogroup B meningococcal disease : a cost-effectiveness study

141 p.
ill.
LIST OF FIGURES 5 -- LIST OF TABLES .8 -- LIST OF ABBREVIATIONS .11 -- SCIENTIFIC REPORT 13 -- 1 BACKGROUND 13 -- 1.1 INVASIVE MENINGOCOCCAL DISEASE .13 -- 1.2 MENINGOCOCCAL CARRIAGE 14 -- 1.3 VACCINES AGAINST MENINGOCOCCAL DISEASE 14 -- 1.4 RESEARCH QUESTIONS .14 -- 2 BELGIAN DATABASES AND MATCHING 16 -- 2.1 DATABASE SOURCES 16 -- 2.2 MATCHING OF THE MZG-RHM AND NRC DATABASES 17 -- 3 BURDEN OF SEROGROUP B MENINGOCOCCAL DISEASE 18 -- 3.1 MEDICAL BURDEN 18 -- 3.1.1 Incidence and age distribution 18 -- 3.1.2 Temporal trends 19 -- 3.1.3 Distribution of vaccine-preventable strains .21 -- 3.1.4 Regional variations 21 -- 3.1.5 Clinical picture 23 -- 3.1.6 Mortality and case fatality ratio .23 -- 3.1.7 Long-term complications and sequelae 24 -- 3.2 QUALITY OF LIFE BURDEN 28 -- 3.2.1 Methods.28 -- 3.2.2 Results 28 -- 4 VACCINE EFFICACY AND SAFETY 34 -- 4.1 VACCINE EFFICACY AGAINST DISEASE 34 -- 4.1.1 SBA responses against the four vaccine components .34 -- 4.1.2 Persistence of hSBA responses 36 -- 4.1.3 Correlation between SBA and clinical protection .37 -- 4.1.4 Predicted strain coverage of the 4CMenB vaccine .38 -- 4.1.5 Relation between MATS and SBA 39 -- 4.2 VACCINE EFFICACY AGAINST CARRIAGE 39 -- 4.3 VACCINE ADVERSE EVENTS 40 -- 5 ANALYTICAL CHOICES FOR THE ECONOMIC EVALUATION OF 4CMENB IN BELGIUM .42 -- 5.1 MODELS STRUCTURE 42 -- 5.1.1 Model structure - details common to both models 42 -- 5.1.2 Model structure – static specific details 42 -- 5.1.3 Model structure – dynamic specific details .42 -- 5.2 OUTCOMES AND COMPARATOR 44 -- 5.3 PERSPECTIVE 44 -- 5.4 TIME HORIZON 44 -- 5.5 DISCOUNTING 44 -- 5.6 DEMOGRAPHICS 44 -- 5.7 INTERPRETATION OF THE COST-EFFECTIVENESS RESULTS .45 -- 6 INPUT FOR THE MODELS45 -- 6.1 VACCINATION STRATEGIES .45 -- 6.1.1 Vaccination schedules 45 -- 6.1.2 Vaccine uptakes to be simulated .47 -- 6.2 CLINICAL / EPIDEMIOLOGICAL PARAMETERS .48 -- 6.2.1 Age-specific incidence rates 48 -- 6.2.2 4CMenB preventable disease 48 -- 6.2.3 Case fatality ratio